<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04036994</url>
  </required_header>
  <id_info>
    <org_study_id>19.58/ONCO19.08</org_study_id>
    <nct_id>NCT04036994</nct_id>
  </id_info>
  <brief_title>PBMT for the Management of CIA ( HAIRLASER )</brief_title>
  <official_title>Photobiomodulation Therapy for the Management of Chemotherapy-induced Alopecia: a Randomized, Placebo-controlled Feasibility Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hasselt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jessa Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hasselt University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chemotherapy (CT) remains an important treatment modality for breast cancer patients.&#xD;
      Unfortunately, this systemic treatment comes with many quality of life impairing&#xD;
      complications. Chemotherapy-induced alopecia (CIA) occurs in about 65% of the patients. Hair&#xD;
      loss due to CT is reversible, but hair regrowth requires several months to a year after CT.&#xD;
      Currently, the only available preventive measure is based on scalp cooling. Nevertheless,&#xD;
      this treatment has a highly variable success rate and it brings along several side effects.&#xD;
      Photobiomodulation therapy (PBMT) is a new, preventive and therapeutic technique in the&#xD;
      supportive care of cancer patients. It uses visible and (near)- infrared light produced by&#xD;
      laser diodes or light emitting diodes (LED) at a low power to stimulate tissue repair and&#xD;
      reduce inflammation and pain. The investigator's research team demonstrated already that PBMT&#xD;
      can prevent oral mucositis and acute radiodermatitis. The aim of this project is to explore&#xD;
      the use of PBMT in the management of CIA. Results of this project will lead to an improvement&#xD;
      of the patients' quality of life after CT.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 17, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>visual analogue scale (VAS)</measure>
    <time_frame>Baseline</time_frame>
    <description>A mechanical visual analogue scale (VAS) will be used to evaluate the patients' hair regrowth based on photographs taken at the four time points. The patients will be asked to indicate their subjective experience of hair regrowth. This score is associated with a certain score, in which 0 = 'total baldness' and 10 = 'full scalp coverage'.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>visual analogue scale (VAS)</measure>
    <time_frame>Month 1</time_frame>
    <description>A mechanical visual analogue scale (VAS) will be used to evaluate the patients' hair regrowth based on photographs taken at the four time points. The patients will be asked to indicate their subjective experience of hair regrowth. This score is associated with a certain score, in which 0 = 'total baldness' and 10 = 'full scalp coverage'.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>visual analogue scale (VAS)</measure>
    <time_frame>Month 2</time_frame>
    <description>A mechanical visual analogue scale (VAS) will be used to evaluate the patients' hair regrowth based on photographs taken at the four time points. The patients will be asked to indicate their subjective experience of hair regrowth. This score is associated with a certain score, in which 0 = 'total baldness' and 10 = 'full scalp coverage'.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>visual analogue scale (VAS)</measure>
    <time_frame>Month 3</time_frame>
    <description>A mechanical visual analogue scale (VAS) will be used to evaluate the patients' hair regrowth based on photographs taken at the four time points. The patients will be asked to indicate their subjective experience of hair regrowth. This score is associated with a certain score, in which 0 = 'total baldness' and 10 = 'full scalp coverage'.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>EORTC QLQ-C30 Quality of life questionnaire</measure>
    <time_frame>Baseline</time_frame>
    <description>A validated questionnaire of the European Organization for Research and Treatment-QOL questionnaire and breast cancer specific module</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EORTC QLQ-C30 Quality of life questionnaire</measure>
    <time_frame>Month 1</time_frame>
    <description>A validated questionnaire of the European Organization for Research and Treatment-QOL questionnaire and breast cancer specific module</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EORTC QLQ-C30 Quality of life questionnaire</measure>
    <time_frame>Month 2</time_frame>
    <description>A validated questionnaire of the European Organization for Research and Treatment-QOL questionnaire and breast cancer specific module</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EORTC QLQ-C30 Quality of life questionnaire</measure>
    <time_frame>Month 3</time_frame>
    <description>A validated questionnaire of the European Organization for Research and Treatment-QOL questionnaire and breast cancer specific module</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QLQ-BR23 Quality of life questionnaire</measure>
    <time_frame>Baseline</time_frame>
    <description>A validated questionnaire of the European Organization for Research and Treatment-QOL questionnaire and breast cancer specific module</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QLQ-BR23 Quality of life questionnaire</measure>
    <time_frame>Month 1</time_frame>
    <description>A validated questionnaire of the European Organization for Research and Treatment-QOL questionnaire and breast cancer specific module</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QLQ-BR23 Quality of life questionnaire</measure>
    <time_frame>Month 2</time_frame>
    <description>A validated questionnaire of the European Organization for Research and Treatment-QOL questionnaire and breast cancer specific module</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QLQ-BR23 Quality of life questionnaire</measure>
    <time_frame>Month 3</time_frame>
    <description>A validated questionnaire of the European Organization for Research and Treatment-QOL questionnaire and breast cancer specific module</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient global satisfaction numerical rating scale</measure>
    <time_frame>Month 3</time_frame>
    <description>The patients' global satisfaction with the PBMT/sham therapy will be evaluated using a numerical rating scale (NRS) from 0 (minimum score) to 10 (maximum score)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Chemotherapy-induced Alopecia</condition>
  <condition>Alopecia</condition>
  <arm_group>
    <arm_group_label>Experimental: Treatment group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham Comparator: Control group</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Photobiomodulation therapy</intervention_name>
    <description>All patients will undergo photobiomodulation therapy sessions twice-weekly for the total duration of 12 weeks starting at their last CT administration.</description>
    <arm_group_label>Experimental: Treatment group</arm_group_label>
    <other_name>Low level laser therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham photobiomodulation therapy</intervention_name>
    <description>All patients will undergo placebo photobiomodulation therapy sessions twice-weekly for the total duration of 12 weeks starting at their last CT administration.</description>
    <arm_group_label>Sham Comparator: Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Informed Consent as documented by signature.&#xD;
&#xD;
               -  Age 18 years or above&#xD;
&#xD;
               -  Female&#xD;
&#xD;
               -  Premenopausal before CT&#xD;
&#xD;
               -  Use of a wig for at least 2 hours a day&#xD;
&#xD;
               -  Able to read and converse in Dutch&#xD;
&#xD;
               -  Skin type I to IV on the Fitzpatrick Skin Type Scale&#xD;
&#xD;
               -  Diagnosis of non-invasive (stage 0) or invasive (stage 1, 2 and 3A) breast&#xD;
                  adenocarcinoma.&#xD;
&#xD;
          -  Page 3 of 5 [DRAFT] -&#xD;
&#xD;
               -  Treatment with neoadjuvant (preoperative) or adjuvant (postoperative)&#xD;
                  chemotherapy: anthracycline and taxane containing (paclitaxel or docetaxel)&#xD;
                  chemotherapy regimen.&#xD;
&#xD;
               -  Diagnosed with CIA grade 2 according to Common Terminology Criteria for Adverse&#xD;
                  Events (CTCAE)&#xD;
&#xD;
               -  Have no documented or observable psychiatric or neurological disorders that might&#xD;
                  interfere with study participation (e.g., dementia or psychosis).&#xD;
&#xD;
               -  Have no diagnosis of ethanol addiction or dependence within the past 10 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Metastatic disease&#xD;
&#xD;
               -  Severe or unstable cardio- respiratory or musculoskeletal disease&#xD;
&#xD;
               -  Pregnancy&#xD;
&#xD;
               -  Presence of cognitive impairment that might impact study outcomes&#xD;
&#xD;
               -  Previously (before start of chemotherapy) diagnosed with a hair loss condition&#xD;
&#xD;
               -  Receiving scalp cooling during chemotherapy&#xD;
&#xD;
               -  Postmenopausal before chemotherapy&#xD;
&#xD;
               -  Active infection on the scalp&#xD;
&#xD;
               -  Chronic dermatologic condition (e.g. eczema, psoriasis, infection)&#xD;
&#xD;
               -  Take any of the following medications for 6 months prior to initiation of the&#xD;
                  study: minoxidil, finasteride (or any other 5Î±-reductase inhibitor medications),&#xD;
                  medications with anti-androgenic properties (e.g. cyproterone, spironolactone,&#xD;
                  ketoconazole, flutamide and bicalutamide)n medications that can potentially cause&#xD;
                  hypertrichosis (ciclosporin, diazoxide, phenytoin and psoralens), and oral&#xD;
                  glucocorticoids&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeroen Mebis, prof. dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jessa Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joy Lodewijckx, drs.</last_name>
    <role>Study Chair</role>
    <affiliation>Hasselt University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jeroen Mebis, prof. dr.</last_name>
    <phone>+ 32 11 33 79 79</phone>
    <email>jeroen.mebis@jessazh.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Joy Lodewijckx, drs.</last_name>
    <phone>+32 11 33 72 29</phone>
    <email>joy.lodewijckx@uhasselt.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Jessa Ziekenhuis</name>
      <address>
        <city>Hasselt</city>
        <zip>3500</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeroen Mebis, prof.dr.</last_name>
      <email>jeroen.mebis@jessazh.be</email>
    </contact>
    <contact_backup>
      <last_name>Joy Lodewijckx, drs.</last_name>
      <email>joy.lodewijckx@uhasselt.be</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 25, 2019</study_first_submitted>
  <study_first_submitted_qc>July 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 30, 2019</study_first_posted>
  <last_update_submitted>August 31, 2021</last_update_submitted>
  <last_update_submitted_qc>August 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hasselt University</investigator_affiliation>
    <investigator_full_name>Prof. dr. Jeroen Mebis</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>photomodulation therapy</keyword>
  <keyword>supportive cancer care</keyword>
  <keyword>epirubicin cyclophosphamide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alopecia</mesh_term>
    <mesh_term>Alopecia Areata</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

